---
document_datetime: 2025-12-29 07:07:57
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/dengvaxia.html
document_name: dengvaxia.html
version: success
processing_time: 0.1152987
conversion_datetime: 2025-12-30 07:44:17.532307
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Dengvaxia

[RSS](/en/individual-human-medicine.xml/67158)

##### Withdrawn

This medicine's authorisation has been withdrawn

dengue tetravalent vaccine (live, attenuated) Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Dengvaxia](#news-on)
- [More information on Dengvaxia](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 21 October 2025, the European Commission withdrew the marketing authorisation for Dengvaxia (dengue tetravalent vaccine (live, attenuated)) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Sanofi Winthrop Industrie, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Dengvaxia was granted marketing authorisation in the EU on 12 December 2018 for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2023.

Dengvaxia : EPAR - Medicine overview

Reference Number: EMA/688282/2021

English (EN) (127.73 KB - PDF)

**First published:** 18/12/2018

**Last updated:** 04/12/2025

[View](/en/documents/overview/dengvaxia-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-906)

български (BG) (154.41 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/bg/documents/overview/dengvaxia-epar-medicine-overview_bg.pdf)

español (ES) (126.21 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/es/documents/overview/dengvaxia-epar-medicine-overview_es.pdf)

čeština (CS) (150.35 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/cs/documents/overview/dengvaxia-epar-medicine-overview_cs.pdf)

dansk (DA) (152.48 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/da/documents/overview/dengvaxia-epar-medicine-overview_da.pdf)

Deutsch (DE) (131.22 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/de/documents/overview/dengvaxia-epar-medicine-overview_de.pdf)

eesti keel (ET) (112.98 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/et/documents/overview/dengvaxia-epar-medicine-overview_et.pdf)

ελληνικά (EL) (181.92 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/el/documents/overview/dengvaxia-epar-medicine-overview_el.pdf)

français (FR) (128.02 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/fr/documents/overview/dengvaxia-epar-medicine-overview_fr.pdf)

hrvatski (HR) (173.59 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/hr/documents/overview/dengvaxia-epar-medicine-overview_hr.pdf)

italiano (IT) (151.22 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/it/documents/overview/dengvaxia-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (167.61 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/lv/documents/overview/dengvaxia-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (155.57 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/lt/documents/overview/dengvaxia-epar-medicine-overview_lt.pdf)

magyar (HU) (184.27 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/hu/documents/overview/dengvaxia-epar-medicine-overview_hu.pdf)

Malti (MT) (175.05 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/mt/documents/overview/dengvaxia-epar-medicine-overview_mt.pdf)

Nederlands (NL) (152.86 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/nl/documents/overview/dengvaxia-epar-medicine-overview_nl.pdf)

polski (PL) (189.68 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/pl/documents/overview/dengvaxia-epar-medicine-overview_pl.pdf)

português (PT) (153.8 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/pt/documents/overview/dengvaxia-epar-medicine-overview_pt.pdf)

română (RO) (172.62 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/ro/documents/overview/dengvaxia-epar-medicine-overview_ro.pdf)

slovenčina (SK) (185.93 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/sk/documents/overview/dengvaxia-epar-medicine-overview_sk.pdf)

slovenščina (SL) (181.96 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/sl/documents/overview/dengvaxia-epar-medicine-overview_sl.pdf)

Suomi (FI) (150.13 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/fi/documents/overview/dengvaxia-epar-medicine-overview_fi.pdf)

svenska (SV) (151.01 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/sv/documents/overview/dengvaxia-epar-medicine-overview_sv.pdf)

Dengvaxia : EPAR - Risk management plan summary

English (EN) (230.58 KB - PDF)

**First published:** 26/01/2022

**Last updated:** 04/12/2025

[View](/en/documents/rmp-summary/dengvaxia-epar-risk-management-plan-summary_en.pdf)

## Product information

Dengvaxia : EPAR - Product information

English (EN) (481.92 KB - PDF)

**First published:** 18/12/2018

**Last updated:** 04/12/2025

[View](/en/documents/product-information/dengvaxia-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-998)

български (BG) (715.74 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/bg/documents/product-information/dengvaxia-epar-product-information_bg.pdf)

español (ES) (646.34 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

15/01/2025

[View](/es/documents/product-information/dengvaxia-epar-product-information_es.pdf)

čeština (CS) (601.1 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/cs/documents/product-information/dengvaxia-epar-product-information_cs.pdf)

dansk (DA) (683.89 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/da/documents/product-information/dengvaxia-epar-product-information_da.pdf)

Deutsch (DE) (575.08 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/de/documents/product-information/dengvaxia-epar-product-information_de.pdf)

eesti keel (ET) (517.91 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/et/documents/product-information/dengvaxia-epar-product-information_et.pdf)

ελληνικά (EL) (653.63 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/el/documents/product-information/dengvaxia-epar-product-information_el.pdf)

français (FR) (644.24 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/fr/documents/product-information/dengvaxia-epar-product-information_fr.pdf)

hrvatski (HR) (606.24 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/hr/documents/product-information/dengvaxia-epar-product-information_hr.pdf)

íslenska (IS) (507.58 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/is/documents/product-information/dengvaxia-epar-product-information_is.pdf)

italiano (IT) (754.23 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/it/documents/product-information/dengvaxia-epar-product-information_it.pdf)

latviešu valoda (LV) (591.91 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/lv/documents/product-information/dengvaxia-epar-product-information_lv.pdf)

lietuvių kalba (LT) (582.43 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/lt/documents/product-information/dengvaxia-epar-product-information_lt.pdf)

magyar (HU) (676.82 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/hu/documents/product-information/dengvaxia-epar-product-information_hu.pdf)

Malti (MT) (758.71 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/mt/documents/product-information/dengvaxia-epar-product-information_mt.pdf)

Nederlands (NL) (718.88 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/nl/documents/product-information/dengvaxia-epar-product-information_nl.pdf)

norsk (NO) (538.3 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/no/documents/product-information/dengvaxia-epar-product-information_no.pdf)

polski (PL) (675.72 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/pl/documents/product-information/dengvaxia-epar-product-information_pl.pdf)

português (PT) (673.72 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/pt/documents/product-information/dengvaxia-epar-product-information_pt.pdf)

română (RO) (635.25 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/ro/documents/product-information/dengvaxia-epar-product-information_ro.pdf)

slovenčina (SK) (608.69 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/sk/documents/product-information/dengvaxia-epar-product-information_sk.pdf)

slovenščina (SL) (606.99 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/sl/documents/product-information/dengvaxia-epar-product-information_sl.pdf)

Suomi (FI) (591.72 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/fi/documents/product-information/dengvaxia-epar-product-information_fi.pdf)

svenska (SV) (522.48 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/sv/documents/product-information/dengvaxia-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** T/0033 12/12/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Dengvaxia : EPAR - All authorised presentations

English (EN) (74.11 KB - PDF)

**First published:** 18/12/2018

**Last updated:** 04/12/2025

[View](/en/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-877)

български (BG) (83.43 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/bg/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_bg.pdf)

español (ES) (73.62 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/es/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_es.pdf)

čeština (CS) (78.96 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/cs/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (61.54 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/da/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (60.45 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/de/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (60.08 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/et/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (76.49 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/el/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_el.pdf)

français (FR) (60.03 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/fr/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (162.99 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/hr/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (60.99 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/is/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_is.pdf)

italiano (IT) (59.02 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/it/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (78.98 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/lv/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (97.36 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/lt/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (94.31 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/hu/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (82.36 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/mt/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (60.55 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/nl/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (59.91 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/no/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_no.pdf)

polski (PL) (82.4 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/pl/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_pl.pdf)

português (PT) (61.65 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/pt/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_pt.pdf)

română (RO) (76.71 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/ro/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (80.55 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/sk/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (87.49 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/sl/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (59.01 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/fi/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (59.89 KB - PDF)

**First published:**

18/12/2018

**Last updated:**

04/12/2025

[View](/sv/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Dengvaxia Active substance

- chimeric yellow fever dengue virus serotype 1 (live, attenuated)
- chimeric yellow fever dengue virus serotype 2 (live, attenuated)
- chimeric yellow fever dengue virus serotype 3 (live, attenuated)
- chimeric yellow fever dengue virus serotype 4 (live, attenuated)

International non-proprietary name (INN) or common name dengue tetravalent vaccine (live, attenuated) Therapeutic area (MeSH) Dengue Anatomical therapeutic chemical (ATC) code J07BX

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

Dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4.2, 4.4 and 4.8).

The use of Dengvaxia should be in accordance with official recommendations.

## Authorisation details

EMA product number EMEA/H/C/004171 Marketing authorisation holder

Sanofi Winthrop Industrie

82 Avenue Raspail 94250 Gentilly France

Opinion adopted 17/10/2018 Marketing authorisation issued 12/12/2018 Withdrawal of marketing authorisation 21/10/2025 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Dengvaxia : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (201.71 KB - PDF)

**First published:** 23/10/2019

**Last updated:** 04/12/2025

[View](/en/documents/procedural-steps-after/dengvaxia-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Dengvaxia-H-C-4171-II-12 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/754269/2021

English (EN) (4.61 MB - PDF)

**First published:** 26/01/2022

**Last updated:** 04/12/2025

[View](/en/documents/variation-report/dengvaxia-h-c-4171-ii-12-epar-assessment-report-variation_en.pdf)

Dengvaxia-H-C-4171-II-11 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/754271/2021

English (EN) (2.13 MB - PDF)

**First published:** 26/01/2022

**Last updated:** 04/12/2025

[View](/en/documents/variation-report/dengvaxia-h-c-4171-ii-11-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Dengvaxia (II-11;II-12)

Adopted

Reference Number: EMA/CHMP/618604/2021

English (EN) (136.48 KB - PDF)

**First published:** 12/11/2021

**Last updated:** 04/12/2025

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-dengvaxia-ii-11ii-12_en.pdf)

Dengvaxia-H-C-4171-II-0003-G : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/553606/2019

English (EN) (1.5 MB - PDF)

**First published:** 23/10/2019

**Last updated:** 04/12/2025

[View](/en/documents/variation-report/dengvaxia-h-c-4171-ii-0003-g-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

Dengvaxia : EPAR - Public assessment report

Adopted

Reference Number: EMA/791273/2018

English (EN) (4.35 MB - PDF)

**First published:** 18/12/2018

**Last updated:** 04/12/2025

[View](/en/documents/assessment-report/dengvaxia-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Dengvaxia

Adopted

Reference Number: EMA/CHMP/666423/2018

English (EN) (121.1 KB - PDF)

**First published:** 19/10/2018

**Last updated:** 04/12/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-dengvaxia_en.pdf)

#### News on Dengvaxia

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021) 12/11/2021

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-october-2018) 19/10/2018

[First vaccine for prevention of dengue](/en/news/first-vaccine-prevention-dengue) 19/10/2018

#### More information on Dengvaxia

- [EMEA-001545-PIP01-13-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001545-pip01-13-m02)
- [A Pregnancy Registry to Evaluate the Safety of Dengue Vaccine among Inadvertently Exposed Pregnant Women and their Offsprings - post-authorisation study](https://catalogues.ema.europa.eu/study/46441)
- [Post-Authorization Safety Study Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine (DNG15-Post Authorisation safety Surveillance study) - post-authorisation study](https://catalogues.ema.europa.eu/study/48340)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)
- [Vaccines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A76)

**This page was last updated on** 04/12/2025

## Share this page

[Back to top](#main-content)